Clinical Trials Browser

Phase 1/2 × onvansertib × Gastrointestinal × Clear all

NCT03829410 2025-03-04

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Phase 1/2 Completed

68 enrolled 21 charts

Gastrointestinal

Colorectal Neoplasms

NCT06736717 2025-02-06

PANCONVA

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms